A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

por Kratzer, Roland, Sansas, Benoît, Lélu, Karine, Evlachev, Alexei, Schmitt, Doris, Silvestre, Nathalie, Inchauspé, Geneviève, Martin, Perrine
Publicado 2018